Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.

Abstract

Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.

• Authors: Kristian Reich, Xenophon Baraliakos, Laura C Coates, Boni Elewski, Weibin Bao, Torben Kasparek, Corine Gaillez, Effie Pournara, Maher Aassi, Chiara Perella, Alice B Gottlieb
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 187 Issue 3 Pg. 438-441 (09 2022) ISSN: 1365-2133 [Electronic] England
• PMID: 35257363 (Publication Type: Clinical Trial, Phase III, Letter)
• Copyright: © 2022 British Association of Dermatologists.

Chemical References

• Antibodies, Monoclonal, Humanized
• secukinumab

Topics

• Antibodies, Monoclonal, Humanized
• Arthritis, Psoriatic (complications, drug therapy)
• Humans
• Nail Diseases (complications, etiology)
• Nails, Malformed
• Psoriasis (complications, drug therapy)
• Severity of Illness Index